

Antidepressants Terry Broda, RN(EC), BScN, NP-PHC, CDDN Elizabeth Kacew, RN(EC), MScN, NP-PHC





Depression is easily missed in people who have social and communication disabilities, although it is probably more common in people with intellectual disabilities and people with autism than in the general population.

Sheila C Hollins (UK)

Symptoms of depression

2

SOLUTION'S

- Early morning waking
- · Sleeping too much
- · Losing or gaining weight
- · Loss of appetite
- · Low mood with or without diurnal variation
- · Anxiety

- · Social withdrawal
- · Loss of sexual interest
- · Loss of confidence
- Self blame and • inappropriate guilt · Inability to make
- decisions • Difficulty
- concentrating

Symptoms of depression

2 **SOLUTION'S**

- Loss of functional or self-care skills
- Irritability Slowed down thinking
- · Thoughts of death
- Suicidal thoughts/actions or other self harm
- Depressive delusions
- Aggression

DSM-IV Criteria for Major Depression and Behavioral Equivalents in Individuals with Developmental Disabilities SOLUTIONS

2

Five or more of the following symptoms must be present for a minimum of 2 weeks. Symptoms 1 or 2 must be one of the five

I	DSM-IV Criteria	Observed Equivalents in Individuals with Developmental Disabilities	Objective Behaviors Which Might be Measured
	 Depressed Mood, irritable mood in children or adolescents 	Apathetic facial expression with lack of emotional reactivity, irritability, somatic complaints	Measure rates of smiling response to preferred activities, crying episodes, somatic complaints
	 Generalized decrease in interest or pleasure by self-report or observed apathy 	Withdrawal, lack of reinforcers, refusal to participate in previously favored activities	Measure time spent in room, etc.
	 Significant decrease in appetite or weight loss (5% body weight in one month) or significant increase in appetite or weight gain (5% body weight in one month) 	Significant increase or decrease in weight (5% in one month) Significant increase or decrease in appetite (daily)	Measure meal refusals, changes in weight, food stealing or hoarding
	4) Insomnia or hypersomnia	Change in total sleep time	Use sleep chart to record sleep
ſ	ww.solution-s.ca		

DSM-IV Criteria	Observed Equivalents in Individuals with Developmental Disabilities	Objective Behaviors Which Might be Measured
 Psychomotor activity or retardation 	Agitation may present SIB or aggression, pacing, running away, restlessness, inability to complete ADLs	Time spent in bed, spontaneous verbalization, pacing
6) Fatigue or loss of energy	Retardation may represent as decreased energy, passivity	Napping at workplace, sleep charts
 Feelings of worthlessness/ inappropriate guilt 	Statements such as, "I'm retarded", "nobody likes me"	Requires expressive language if symptoms are present
 Decreased concentration/ indecisiveness/ diminished ability to think 	Change in workplace performance, regression of skills	Use workplace performance data
 Recurrent thought of death/ suicidal ideation 	Perseveration on the deaths of family members and friends, preoccupation with funerals, deliberately potentially lethal acts, SIB	Requires expressive language to determine if symptoms are present



Aetiology

Depression is not caused by a single

factor. There are probably many causes, and the causes can interact with each other. **Vulnerability** factors may be:

- **biological**, e.g. genetic or associated with physical illness.
- psychological, e.g. abuse or bereavement
- social, e.g. relationship problems, poverty or boredom.


www.solution-s.ca

Stressors

Stressors can be very varied, and typically have a perceived element of loss or threat such as:

- bereavement
- caregiver moving to a new job (intense reaction!)
- · change in routine
- · moving residence
- · being a victim of crime and/or abuse
- major illness or a chronic painful condition, e.g.: UTIs, AOMs, cellulitis, constipation, GERD, migraines, & SE of Rx

www.solution-s.ca





Other indications

0

SOLUTION'S

- TCA, duloxetine/venlafaxine : chronic pain, fibromyalgia, migraine, premenstrual disorder
- · SSRI : premenstrual disorder
- Buproprion : smoking cessation, ADHD
- Trazadone : bulimia, insomnia, challenging behaviors for those with dementia

www.solution-s.ca



DO NOT MEDICATE ENVIRONMENT

1999 - 1999 - 1999 - 1999 - 1999 - 1999 - 1999 - 1999 - 1999 - 1999 - 1999 - 1999 - 1999 - 1999 - 1999 - 1999 -

Antidepressants


- Tricyclic Antidepressants
 Amitriptyline (Elavil), clomipramine (Anafranil), imipramine (Tofranil), doxepine
 (Sinequan)
- Monoamine Oxydase Inhibiters (reversible)
 Phenelzine (Nardil), tranylcypromine (Parnate), moclobernide (Manerix)
- Selective Serotonin reuptake Inhibiters (SSRI)
 Escitalopram (Cipralex), Citalopram (Celexa), fluoxetine (Prozac),
 Paroxetine (Paxil), fluvoxamine (Luvox), sertraline (Zoloft)


Antidepressants

SOLUTIO∩·S


- Serotonin-2 antagonist/IRS: Trazadone (Desyrel)
- Other antidepressants:
- norepinephrine(N), serotonin (S) & dopamine (D):
- Duloxetine (Cymbalta), Desvenlafaxine (Pristiq), Venlafaxine (Effexor), N & S: Mirtazapine (Remeron); N & D: Buproprion (Wellbutrin)

www.solution-s.ca











			Adverse R	eactions ^a				
Drug	Sedation	Orthostatic Hypotension	Constipation/ Dry Mouth	Cardio- toxicity	Insomnia	Weight Gain	Jitteriness	Seizures
amitriptyline	+++	+++	+++	+++	+	+++	0	++
amoxapine	+	++	+++	++	++	0/+	0/+	++
clomipramine	+++	++	+++	++	+	++	++	+++
desipramine	+	+	+	+++	+	+	++	+
doxepin	+++	++	+++	++	+	+++	+	+
imipramine	++	+++	++	+++	++	+++	+++	++
maprotiline	++	+	++	++	+	++	++	+++
nortriptyline	+	+	++	++	+	+	++	+
protriptyline	0/+	++	+++	++	+++	+	++	+
trimipramine	+++	++	++	++	+	++	+	+
Note. Adapted fi	rom Maxmen (1990) and Preskor	m (1993).					
a +++ = marke	effects ++ =	moderate effects	+ = weak effects,	0 = none	Reis	s S., & Ama	ın, M. (ed's). (1	1998).

Reaction	Amitriptyline	Clonipramine	Desipramine	Daxepin	Imipramine	Nortriptyline	Protriptyline	Trimipramine	Amoxapine	Maprotilin
ONS Effects										
Depwsiness, sedation	> 30%	> 2%	> 2%	> 30%	> 10%	> 2%	< 2%	> 30%	> 10%	> 10%
niomnia	> 2%	> 10%	> 2%	> 2%	> 10%	< 2%	> 10%	> 2%"	> 10%	< 2%
acitement, hypomania*	< 2%	< 2%	> 2%	< 2%	> 10%	> 2%	> 10%	< 2%	> 2%	> 2%
lisorientation/confusion	> 10%	> 2%		< 2%	> 2%	> 10%		> 10%	> 2%	> 2%
teadache	> 2%	> 2%	< 2%	< 2%	> 10%	< 2%		> 2%	> 2%	< 2%
tothenia, faligue	> 10%	> 25	> 2%	> 25	> 1295	> 10%	> 10%	> 2%	> 2%	> 2%
Anticholinergic Effects										
Dry mouth	> 30%	> 30%	> 10%	> 30%	> 30%	> 10%	> 10%	> 10%	> 30%	> 30%
Burred vision	> 10%	> 10%	> 25	> 102%	> 10%	> 2%	> 10%	> 2%	> 2%	> 10%
Constigation	> 10%	> 10%	> 2%	> 10%	> 10%	> 10%	> 10%	> 10%	> 30%	> 10%
Sweating	>10%	> 10%	> 2%	> 2%	> 10%	< 2%	> 10%	> 2%	> 2%	> 2%
Delayed micturition**	> 2%	> 25		< 2%	> 10%	< 2%	< 2%	< 2%	> 10%	> 2%
Extrapyramidal Effects										225
Unspecified	> 257	< 2%*	< 2%	> 2%	< 2%	-	-	< 2%	> 2%"	> 2%
Tremor	> 10%	> 10%	> 2%	> 2%	> 10%	> 10%	> 2%	> 10%	> 2%	> 10%
Cardiovascular Effects								1000	19224	0.000
Orthostatic hypotension/dizziness	> 10%	> 10%	> 2%	> 10%	> 30%	> 2%	> 10%	> 10%	> 10%	> 2%
Tachycardia, pulpitations	> 10%	> 10%	> 10%	> 2%	> 10%	> 2%	> 2%	> 2%	> 10%	> 2%
ECG changes***	> 10%*	> 10%20	> 2% 11	> 2%"	> 10%*	> 2%*	> 1096*	> 10%**	< 2%"	< 29/1
Cardiac arrhythmia	> 2%	> 2%	> 2%	> 2%	> 2%	> 2%	> 2%	> 2%	< 2%	< 2%
GI distress	> 2%	> 10%	> 2%	< 2%	> 10%	< 2%	-	< 2%	> 2%	> 2%
Dermatitis, rash	> 2%	> 2%	> 2%	< 2%	> 2%	< 2%	< 2%	< 2%	> 10%	> 10%
Weight gain (over 6 kg)	> 30%	> 10%	> 2%	> 10%	> 10%	> 2%	< 2%	> 10%	< 2%	
Sexual disturbances	> 2%	> 30%	> 2%	> 2%	> 30%	< 2%	< 2%	< 2%	> 2%	< 2%
Seitures ⁵⁰	< 2%	< 2% ^a	< 2%	< 2%	< 2%	¢ 2%	< 2%	< 2%	< 2%"	< 2% ¹⁰

www.solution-s.ca

Virani, Bezchlibnyk-Butler & Jeffries, 2009

Anticholinergic Side Effects

- · Blurry vision
- Nasal congestion
- Dry mouth
- · Urinary retention
- Constipation




2

SOLUTION'S


Rx : tricyclic antidepressants







Adapted from CANMAT (1999)




					Adverse 1	Reactions ^a				
Drug	Sedation		Constipation/ Dry Mouth		Insomnia	Nausea/ Vomiting		Irritability	Head- aches	Seizure
fluoxetine	+	0	+	0/+	++	++	+	++	++	+
fluvoxamine	+	0	+	0/+	+	++	++	+	++	+
nefazodone	++	+	+	0/+	+	++	++	+	+	+
paroxetine	+	+	+	0/+	+	++	++	+	++	+
sertraline	++	0	+	0/+	+	++	++	+	++	+
trazodone	+++	++	+	0/+	0	++	++	+	+	+
venlafaxine	+	0	+	0/+	+	++	+	+	++	+
bupropion	++	0	+	0/+	++	+	+	++	++	+/++
Note. Adapted	from Drug	Facts and Con	nparisons (1995)				Reiss S., &	Aman, M. (e	ed's). (1	998).

Frequency of Adverse Reactions to Cyclic Antidepressants at Therapeutic Doses (cont.)

	4		NDRI	9	NRI .				\$\$	1		-	NaSSA
teaction	Trazo- done	Nefazo- done	Bupro- pion	Venlafax- ine	Desvenla- faxine	Daloxe- tine	Citalopram	Escitalo- pram	Fluoxetine	Flavoxa- mine	Paroxetine	Sertraline	Mirtazapin
CNS Effects								9308	> 10%	> 10%	> 10%	> 10%	> 30%*
Drowsiness, sedation	> 30%	> 30%	> 2%	> 10%	> 32%	> 10%	> 10%	> 2%		> 10%	> 10%	> 10%	> 2%
insonnia	> 2%	> 2%	> 10%	> 10%"	> 10%	> 10%	> 10%	> 10%	> 10%"	> 10%	> 2%	> 10%	> 2%
Excitement, hypomania*		> 2%	> 10%*	> 10%	> 3%	< 2%	> 2%	< 2%	> 2%		5 2%	< 2%	> 2%
Disorientation/confusion	< 2%	> 10%	> 2%	> 2%	2		< 2%	< 2%	> 10%	> 2%	> 10%	> 10%	> 2%
Headache	> 2%	> 30%	> 10%	> 10%	> 3%	> 10%	> 10%	< 2%	> 10%			> 2%	> 10%
Asthenia, fatigae	> 10%	> 10%	> 2%	> 10%	> 10%	> 10%	> 10%	> 2%	> 10%	> 10%	> 10%	1.29	1 1019
Articholinergic Effects			1					> 125	> 10%	> 10%	> 10%	> 10%	> 30%
Dry mouth	> 12%	> 10%	> 1055	> 10%	> 10%	> 10%	> 1056	3 8/06	> 2%	> 2%	> 2%	> 2%	> 10%
Blurred vision	> 2%1	> 10%	> 10%	> 2%	> 3%	> 2%	> 2%	> 2%	> 25	> 12%	> 10%	> 2%	> 10%
Constigation	> 2%	> 10%	> 10%	> 10%	> 10%	> 10%	> 2%		> 2%	> 10%	> 10%	> 2%	> 2%
Sweating		> 2%	> 1016	> 10%	> 10%	> 10%	> 12%	> 2%	> 2%	> 2%	> 2%	c 2%	> 25
Delayed micturition**	c.2%	< 2%	> 2%	< 2%	1	< 2%	> 2%	-	7.65	1 6.0			
Extraoyramidal Effects					5	1.2%	> 2%	< 2%	< 25	> 296	> 2%	> 2%	> 2%
Unspecified	> 2%*	< 2%	< 2%	> 2%			> 2%	< 2%	> 10%	>10%	> 10%	> 10%	> 2%
Tremor	> 2%	< 2%	> 10%	> 2%	2	> 2%	> 2h	\$ 2.0	7 10/4	- 10.0			
Cardiovascular Effects				> 10%*	> 1057	>10%*	> 2%	> 2%	> 10%	> 2%	> 10%	> 10%	> 2%
Orthostatic hypotension/dizziness	> 10%	> 10%	> 2%		> 3%	> 2%	> 250	> 250	< 25P ¹	< 29/1	> 2%	> 2%	> 2%
Tachycardia, palpitations	> 2%	< 2%	> 2%	> 2% ¹¹	25	- 20	< 2%	< 2%	\$ 2%	< 2%	c 2%	< 2%	< 2%
ECG changes***	> 2%	< 2%	< 2%	< 2%"	< 2h		\$ 2%	< 2%	< 2% ⁴	< 2%	< 2%	< 25	< 2%
Cardiac anhythmia	> 2%10	< 2%	< 2%	< 2%	> 30%	> 10%	> 10%	> 10%	> 10%	> 30%	> 10%	> 30%	> 2%
GI distress	> 10%	> 10%	> 10%	> 30%	> 90%	> 10%	< 2%	> 2%	> 2%	> 2%	< 2%	> 2%	< 2%
Dermatitis, rash	< 2%	< 2%	> 2%	> 2%		> 2%	> 2%	< 2%	> 2%	> 2%	> 109/1	> 257	> 30%
Weight gain (over 6 kg)"	> 2%	> 2%	< 2%	> 2%	7	> 30%	> 30%	> 10%	> 30%**	> 30%	> 30%	> 30%"	> 2%
Sexual disturbances	< 2%	> 2%	€ 250%		> 3%	> 50%	< 2%	< 2%	< 25	< 2%	< 2%	< 2%	< 2%
Seizures ⁱⁿ - None reported in literature persond, ¹ Mi	× 2%	< 2%	< 2%*	< 2%					- 10				









ww	w.sc	luti	ion-	\$.0	а

Dry mouth	Gum, pastilles/cough drops 6-8 glasses H2O/day Special tooth paste	
N & V	Rx with food Crackers, toast	
Weight gain	Diet Exercise	Change Rx
Urinary retention	6-8 glasses H2O/day	
Constipation	6-8 glasses H2O/day Exercise Diet rich in fruits, vegetables & fibre	Laxative
Orthostatic Hypotension	Increase hydratation Get up/change position slowly	
Fatigue/sedation	Planned exercise & rest Avoid alcohol Caffeinated beverages (1/day)	Change Rx Change time of dose Decrease the dose
Blurry vision	Magnifying glasses temporarily	Eye drops
Diaphoresis	Light clothing Showers/baths frequently	Decrease the dose Change Rx
Tremor	May decrease w/ dose decrease	Decrease the dose

Serotonin Syndrome

2 **SOLUTION'S**

Accumulation of serotonin : Symptoms :

- Agitation, confusion
- · Nausea, Diarrhea
- Dizziness
- · Diaphoresis
- Ataxia, Tremor
- Myoclonus, Convulsions
- Hyperreflexia
- w.solution-s.ca
- ↑ BP, Palpitations, tachycardia
- · Hyperthermia/fever
- Rhabdomyolysis
- Severe respiratory
- depression & coma

Withdrawal of SSRIs

Symptoms :

- Dizziness, lethargy, N & V, diarrhea, headache, fever, diaphoresis, malaise, insomnia, intense dreams, myalgia, paresthesia, sensations of 'electric shock', anxiety agitation, irritability, confusion, disorientation, aggression rarely
- 1-7 days after decrease or discontinuation of Rx
- · Duration: 3 weeks
- Tx:
- · Decrease the dose by 25% per week

www.solution-s.ca

Considerations

- · Trazadone at bedtime: on empty stomach
- Active Metabolites : TCAs, fluoxetine
- · Dosing : TCAs, SSRIs : die; others : BID
- Interactions with CYP450 enzymes
- Special diet with MAOIs (^t tyramine)

** Verify the risk of suicide regularly

